| Share this trap: | |
|---|---|
|
|
|
Loading...
The distribution of white matter brain abnormalities in some patients after mild traumatic brain injury (MTBI) closely resembles that found in early Alzheimer's dementia, according to a new study.
The lipidation states (or modifications) in certain proteins in the brain that are related to the development of Alzheimer disease appear to differ depending on genotype and cognitive diseases, and levels of these protein and peptides appear to be influenced by diet, according to a new report.
The lipidation states (or modifications) in certain proteins in the brain that are related to the development of Alzheimer disease appear to differ depending on genotype and cognitive diseases, and levels of these protein and peptides appear to be influenced by diet, according to a report published Online First by JAMA Neurology, a JAMA Network publication.
read...
Amarantus BioScience ( AMBS.OB ) is developing a Lymphocyte Proliferation (LymPro) Blood Test for the diagnosis of Alzheimer's Disease. The company acquired the test from privately-held Memory Dx, LLC, in December 2012. The inventors of the test, Dr. Thomas Arendt and Dr. Jens Stieler of the University of Leipzig, Germany, had previously published data and the mechanism of action for LymPro in NeuroReport. We note that LymPro has completed two phase I clinical studies in over 160 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis...
Researchers say a small, new study shows that fat cut the body's level of a chemical that keeps Alzheimer's at bay
LA JOLLA, Calif., June 17, 2013 — The first experimental drug to boost brain synapses lost in Alzheimer's disease has been developed by researchers at Sanford-Burnham Medical Research Institute. The drug, called NitroMemantine, combines two FDA-approved medicines to stop the destructive cascade of changes in the brain that destroys the connections between neurons, leading to memory loss and cognitive decline.
